PolyPid Q4 Earnings Call Highlights

During the Q&A, Akselbrad said PolyPid is targeting an initial label focused on prevention of surgical site infections in patients undergoing abdominal colorectal surgery, noting that this indication is directly supported by SHIELD II data and aligns with D-PLEX100’s breakthrough therapy designation. She added that the company expects there “may be an opportunity” to evaluate potential label expansion into broader abdominal surgical applications during the review process and said PolyPid plans to meet with ...